Can Boehringer Ingelheim’s Pradaxa be viable in Korean market?

Published: 2011-03-09 06:58:00

Updated: 2011-03-09 06:58:00

The Korea Food and Drug Administration (FDA) has recently approved Pradaxa (dabigatran etexilate) capsules to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

As demonstrated in the previous clinical trials, Pradaxa 150mg taken twice daily has...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK